AI
| Followers | 843 |
| Posts | 122806 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Sunday, July 20, 2008 3:35:10 PM
Re: Quiz answers
>A1: I'd say all but no. 5, Novartis doesn't fully own Alcon yet.
Correct.
>A2: No. 2,3,6,7,9 are considered "merger of equals".<
Not bad—you got all but one. CVS-Caremark (#10) is the one you missed.
>A3: No. 6 (British & Swedish).<
AstraZeneca (#6) is the easy one. The hard one is the Monsanto deal (#9); it qualifies because Pharmacia & Upjohn had dual headquarters in the US and Sweden.
>A4: No. 1 was initially hostile.<
Correct re PFE/Warner-Lambert (#1), but you missed Sanofi-Aventis (#3).
>A5: No. 8 Boston Scientfc/Guidant<
This is the only quiz question of the five that is somewhat subjective. It’s undeniable that Guidant brought Boston Scientific many headaches; however, my vote for the deal least likely to have been made if the dealmakers could have seen the future is PFE-Pharmacia (#4). The main impetus for this colossally expensive ($60B!) deal was Celebrex, which turned out to be a much smaller commercial success than PFE expected.
Nice job. You get an A-/B+
>A1: I'd say all but no. 5, Novartis doesn't fully own Alcon yet.
Correct.
>A2: No. 2,3,6,7,9 are considered "merger of equals".<
Not bad—you got all but one. CVS-Caremark (#10) is the one you missed.
>A3: No. 6 (British & Swedish).<
AstraZeneca (#6) is the easy one. The hard one is the Monsanto deal (#9); it qualifies because Pharmacia & Upjohn had dual headquarters in the US and Sweden.
>A4: No. 1 was initially hostile.<
Correct re PFE/Warner-Lambert (#1), but you missed Sanofi-Aventis (#3).
>A5: No. 8 Boston Scientfc/Guidant<
This is the only quiz question of the five that is somewhat subjective. It’s undeniable that Guidant brought Boston Scientific many headaches; however, my vote for the deal least likely to have been made if the dealmakers could have seen the future is PFE-Pharmacia (#4). The main impetus for this colossally expensive ($60B!) deal was Celebrex, which turned out to be a much smaller commercial success than PFE expected.
Nice job. You get an A-/B+
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
